IVVD Invivyd
Price Chart
Executive Summary
Invivyd dosed first participants in the LIBERTY Phase 3 trial evaluating VYD2311 (mAb) vs. mRNA COVID-19 vaccine, with topline data expected Q3 2026 alongside pivotal DECLARATION trial results. This is an early-stage clinical milestone with no efficacy or safety data yet — a routine pipeline update for a pre-revenue biotech.
Actionable Insight
No efficacy or safety data released — stock reaction likely muted until Q3 2026 topline readouts. Monitor DECLARATION and LIBERTY data for VYD2311's differentiation vs. mRNA vaccines on tolerability. Historical calibration suggests neutral-to-negative drift at T+20 for this ticker; avoid directional positioning ahead of data.
Key Facts
- First participants dosed in LIBERTY Phase 3 trial (N≈210) comparing VYD2311 alone, mRNA vaccine alone, and co-administration.
- Topline data expected Q3 2026, concurrent with pivotal DECLARATION trial data.
- Primary endpoints are safety/tolerability through Day 6 (TEAEs, injection site reactions, systemic symptoms).
- LIBERTY is part of the broader REVOLUTION program aiming to position VYD2311 as a preferred COVID-19 prevention option over mRNA vaccines.
- VYD2311 shares antibody backbone with pemivibart (EUA for immunocompromised PrEP) and adintrevimab.
Financial Impact
No financial data disclosed; pre-revenue clinical-stage biotech.
Risk Factors
- Clinical trial failure or underwhelming safety/tolerability data vs. mRNA vaccines.
- Regulatory hurdles for BLA submission; reliance on EUA for pemivibart may not translate to VYD2311 approval.
- Viral evolution could reduce VYD2311 neutralizing activity against emerging variants.
- Enrollment delays or slower-than-expected recruitment could push Q3 2026 timeline.
Market Snapshot
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3308710 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
Jun 11, 2026
3d ago
|
Institutional Cluster
| $0.8286 awaiting T+5 | awaiting T+5 | — | $0.7700 (−7.07%) |
|
Jun 9, 2026
5d ago
|
Press Release
| $1.02 awaiting T+5 | awaiting T+5 | — | $0.7700 (−24.51%) |
|
Jun 1, 2026
13d ago
|
Press Release
| $1.22 $1.03 | ▼ −15.57% | ▼ −12.82% | $0.7700 (−36.89%) |
|
May 14, 2026
4w ago
|
8-K
| $1.16 $1.11 | ▼ −4.31% | ▼ −3.59% | $0.7700 (−33.62%) |
|
May 14, 2026
4w ago
|
Press Release
| $1.16 $1.11 | ▼ −4.31% | ▼ −3.59% | $0.7700 (−33.62%) |
|
Apr 9, 2026
9w ago
|
8-K
| $1.78 $1.71 | ▼ −3.93% | ▼ −7.12% | $0.7700 (−56.74%) |
|
Apr 9, 2026
9w ago
|
Press Release
| $1.78 $1.71 | ▼ −3.93% | ▼ −7.12% | $0.7700 (−56.74%) |
|
Apr 7, 2026
9w ago
|
Press Release
| $1.29 $1.61 | ▲ +24.81% | ▲ +19.48% | $0.7700 (−40.31%) |
|
Mar 5, 2026
14w ago
|
8-K
| $1.74 $1.80 | ▲ +3.45% | ▲ +5.69% | $0.7700 (−55.75%) |
|
Mar 5, 2026
14w ago
|
Press Release
| $1.74 $1.80 | ▲ +3.45% | ▲ +5.69% | $0.7700 (−55.75%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access